Rezulin Priority Status Is Not Evidence Of Careless Review - Warner-Lambert
Executive Summary
The priority review status granted to Rezulin does not mean that the agency spent less time reviewing the NDA, Warner-Lambert maintained in a letter to House Commerce Committee Chairman Bliley (R-Va.).
You may also be interested in...
FDA ODE II Overhaul Continues: Rarick Returns, Sobel Moves Up
FDA is completing a change of the guard in the Office of Drug Evaluation II with the appointment of Reproductive & Urologic Drug Products Division Director Lisa Rarick, MD, as ODE II deputy director.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011